Larimar Therapeutics, Inc. (LRMR) Form 8-K — May 14, 2026
$LRMRForm 8-KItems 2.02, 8.01, 9.01Filed May 14, 2026, 7:02 AM ET0001193125-26-222746Original filing
Larimar Therapeutics, Inc. reported its first quarter 2026 financial results, including a net loss of $29.6 million, or $0.31 per share. The company also announced a strong cash position of $200.4 million as of March 31, 2026, with a projected cash runway into the second quarter of 2027. The company is making significant progress with its nomlabofusp program for the treatment of Friedreich’s ataxia (FA).
Key figures
- Eps
- -0.31
- Eps Beat
- 0
- Revenue
- 0
- Guidance
- Projected cash runway into the second quarter of 2027
- Net Income
- -29.613
- Total Debt
- 50,478,000
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 208,511,000
- Cash Position
- 200,400,000
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 103,882,937
Price after filing
1 day: 0.0%7 days: -8.2%30 days: -7.5%
Close on the filing date to close N calendar days later (from $3.89). Historical, not a forecast.
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.